Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Citigroup upgrades Larimar Therapeutics to Buy, predicts 284% surge

Published Nov 18, 2023 09:52AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
C
+0.22%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LRMR
-3.71%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

NEW YORK - Citigroup has revised its stance on Larimar Therapeutics (NASDAQ: LRMR), upgrading the stock from Neutral to Buy, with a price target suggesting an impressive 284% potential upside. This optimistic outlook follows a notable increase in institutional investment in the biotech firm, which is currently engaged in developing treatments for Friedreich's ataxia (FA).

Institutional investors have significantly bolstered their positions in Larimar Therapeutics, now holding over 38 million shares across 154 funds. This marks a substantial rise in both the number of shares held and the diversity of institutional backers. Among these, investment firms such as Deerfield Management and CHI Advisors are prominent shareholders, with stakes of 39% and 8% respectively.

Moreover, Verition Fund Management has recently augmented its investment by 6%, showcasing confidence in Larimar's prospects. Similarly, Janus Henderson Group (NYSE:JHG) increased their shareholding by 41%, despite a reduction in their overall portfolio allocation to Larimar by nearly 20%. Citadel Advisors also made adjustments, cutting their stake by 20% but raising their portfolio allocation to the company by almost 9%.

The heightened interest from these institutional players comes as Larimar advances its lead compound, CTI-1601, through Phase 1 clinical trials. CTI-1601 is being investigated as a potential therapeutic agent for FA disease, a debilitating genetic condition for which there are currently limited treatment options.

Citigroup's bullish upgrade reflects broader anticipation among investors that positive clinical developments could propel Larimar's stock value significantly. As the company progresses with its trials, the market will be closely monitored for further updates on CTI-1601's efficacy and safety profile, which could be pivotal for Larimar's future growth trajectory.

InvestingPro Insights

In light of the recent developments, InvestingPro's real-time data and tips offer valuable insights into Larimar Therapeutics. According to InvestingPro, the company holds more cash than debt on its balance sheet and has liquid assets that exceed its short-term obligations, indicating a strong financial position. However, the company has not been profitable over the last twelve months, and analysts do not anticipate the company will turn profitable this year.

From a metrics perspective, Larimar's market cap stands at $144.45M, with a P/E Ratio of -4.33, reflecting the company's current lack of profitability. The company's stock has seen a significant return over the last week, with a 34.29% increase in its price. The InvestingPro Fair Value for Larimar is $3.15, slightly higher than its previous close at $3.09.

InvestingPro offers a wealth of additional tips and data for subscribers, now available at a special Black Friday discount of up to 55%. With these insights, investors can make informed decisions about their investments in Larimar Therapeutics and other companies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Citigroup upgrades Larimar Therapeutics to Buy, predicts 284% surge
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email